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Abstract
Aim: To assess glycaemic control and factors associated with poor glycaemic control
at initiation of second-line therapy in the DISCOVER programme.
Materials and methods: DISCOVER (NCT02322762 and NCT02226822) comprises
two similar prospective observational studies of 15 992 people with type 2 diabetes
(T2D) initiating second-line glucose-lowering therapy in 38 countries across six
regions (Africa, Americas, South-East Asia, Eastern Mediterranean, Europe and West-
ern Pacific). Data were collected using a standardized case report form. Glycated
haemoglobin (HbA1c) levels were measured according to standard clinical practice in
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each country, and factors associated with poor glycaemic control (HbA1c >8.0%)
were evaluated using hierarchical regression models.
Results: HbA1c levels were available for 80.9% of patients (across-region range
[ARR] 57.5%-97.5%); 92.2% (ARR 59.2%-99.1%) of patients had either HbA1c or
fasting plasma glucose levels available. The mean HbA1c was 8.3% (ARR 7.9%-8.7%).
In total, 26.7% of patients had an HbA1c level ≥9.0%, with the highest proportions in
South-East Asia (35.6%). Factors associated with having HbA1c >8.0% at initiation of
second-line therapy included low education level, low country income, and longer
time since T2D diagnosis.
Conclusions: The poor levels of glycaemic control at initiation of second-line therapy
suggest that intensification of glucose-lowering treatment is delayed in many patients
with T2D. In some countries, HbA1c levels are not routinely measured. These
findings highlight an urgent need for interventions to improve monitoring and man-
agement of glycaemic control worldwide, particularly in lower-middle- and upper-
middle-income countries.
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1 | INTRODUCTION
Early achievement of sustained glycaemic control is a key component
of the effective management of patients with type 2 diabetes (T2D),
given the well-established increased risk of diabetes-related complica-
tions associated with hyperglycaemia.1-3 The UK Prospective Diabe-
tes Study demonstrated that an absolute reduction in glycated
haemoglobin (HbA1c) level of 1.0% is associated with risk reductions
of 21%, 14% and 37% for diabetes-related death, myocardial infarc-
tion and microvascular complications, respectively.1 In a 10-year post-
interventional follow-up of the study cohort, early attainment of
glycaemic control was associated with long-term microvascular
benefits,4 and there is also evidence that early attainment of tight
glycaemic control is predictive of long-term glycaemic control.5
On the basis of this evidence, most clinical guidelines advocate a
target HbA1c level of either <7.0% or ≤6.5% depending on additional
patient-specific factors such as age, duration of diabetes, com-
orbidities, and risk of hypoglycaemia.6-10 Treatment intensification is
recommended when patients remain above their HbA1c targets for
>3 months after the last intervention. Despite these recommenda-
tions, available data, mainly from Europe and North America, indicate
poor attainment of glycaemic targets and infrequent implementation
of timely treatment intensification.11-16 Moreover, real-world data on
the management of T2D are scarce in many low- and middle-income
countries, in which the rising disease prevalence is a concern.
DISCOVER is a 3-year, global, prospective, observational study
programme designed to describe the disease management patterns
and a broad range of associated outcomes, including glycaemic con-
trol, in patients with T2D initiating a second-line glucose-lowering
treatment (defined as adding a glucose-lowering drug or switching
between therapies) after first-line (defined as the first pharmacological
treatment given for the disease) oral therapy in routine clinical prac-
tice.17,18 The aim of the present analysis was to describe the level of
glycaemic control in participants in DISCOVER at initiation of second-
line glucose-lowering therapy. Factors associated with poor glycaemic
control were also assessed.
2 | MATERIALS AND METHODS
The methods for the DISCOVER study programme have been
reported in detail elsewhere17,18 and are summarized below.
2.1 | Study design
The global DISCOVER study programme comprises two similar,
3-year, non-interventional, prospective studies conducted simulta-
neously in 38 countries; DISCOVER (NCT02322762) in 37 countries
and J-DISCOVER (NCT02226822) in Japan. Included countries are
divided into regions according to the World Health Organization
(WHO) categories: Africa (Algeria and South Africa); the Americas
(Argentina, Brazil, Canada, Colombia, Costa Rica, Mexico and Panama);
South-East Asia (India and Indonesia); Europe (Austria, Czech Repub-
lic, Denmark, France, Italy, Netherlands, Norway, Poland, Russia,
Spain, Sweden and Turkey); Eastern Mediterranean (Bahrain, Egypt,
Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia and United
Arab Emirates); and the Western Pacific region (Australia, China,
Japan, Malaysia, South Korea and Taiwan). The study protocols were
approved by the appropriate clinical research ethics committees in
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each participating country, and the relevant institutional review
boards at each site. The protocols comply with the Declaration of Hel-
sinki, the International Conference on Harmonization of Good Clinical
Practice, and the local regulations for clinical research.
2.2 | Site and investigator selection
Characteristics of physicians and practices involved in the manage-
ment of patients with T2D were assessed in each participating coun-
try, before the start of the study, by combining data from peer-
reviewed articles, information from reports published by organizations
such as the WHO, and insights from key local diabetes experts who
acted as national coordinating investigators.19 The proportions of dif-
ferent types of physicians (primary care physicians, diabetologists,
endocrinologists, cardiologists and other specialists) and practices (pri-
mary care centres, specialized diabetes centres and different types of
hospitals), as well as the location of practices (urban vs rural and geo-
graphical distribution within a country), treating patients with T2D in
each country were collated. A list of sites that would match these
characteristics as closely as possible was then established for each
country, and all sites were invited to participate in the study.19
2.3 | Patient recruitment
Full inclusion and exclusion criteria are shown in Table S1. Patients
aged >18 years (>20 years in Japan) with T2D, who were initiating a
second-line glucose-lowering therapy were eligible for inclusion if
they were not pregnant, were not undergoing dialysis, did not have a
history of renal transplant, and if their first-line therapy was not an
injectable agent, a herbal remedy, or a natural medicine alone. The
study protocol stated that investigating physicians should invite con-
secutive eligible patients to participate in the study. All participating
patients provided signed informed consent.
2.4 | Data collection
Data were collected at initiation of second-line glucose-lowering ther-
apy using a standardized case report form and transferred to a central
database via a web-based data capture system. Some data were
extracted from existing electronic health records in Canada, Denmark,
France, Norway and Sweden; in these countries, an abbreviated case
report form was used.
Variables collected included: physician and site characteristics;
patient socio-economic demographics; physiological characteristics
including height, weight and seated blood pressure; laboratory test
results including HbA1c level and/or fasting plasma glucose (FPG) at
the time of treatment change; change in glucose-lowering therapies
and reason(s) for change; comorbidities, including diabetes-related
microvascular and macrovascular diseases; and co-medications. In line
with the observational nature of the study, clinical variables, such as
HbA1c levels, were measured and recorded in accordance with rou-
tine clinical practice; data collection was not mandatory for any of the
clinical variables.
2.5 | Statistical analysis
For the present analysis, patients from China (n = 1293) were
excluded because complete data were not available at the time of
publication; therefore, the total number of patients included in the
analysis was 14 699 (91.9% of the total DISCOVER population).
Descriptive data are presented as numbers and percentages for cate-
gorical variables. For continuous variables, mean (SD), median (inter-
quartile range [IQR]), and across-region ranges (ARRs) are reported,
where appropriate.
Factors associated with poor glycaemic control were assessed in
patients with available HbA1c levels using hierarchical logistic regres-
sion models, with country as a random effect. HbA1c was modelled as
a dichotomous variable (≤7.0% vs >7.0%, ≤8.0% vs >8.0%, and ≤9.0%
vs >9.0%) with the following additional variables included in the
models: age; sex; education level; smoking status; body mass index
(BMI); systolic blood pressure (SBP); time since diagnosis of T2D (used
as a proxy for diabetes duration); use of co-medications (angiotensin-
converting enzyme inhibitors or angiotensin receptor blockers,
diuretics, β-blockers, statins and acetylsalicylic acid); first-line glucose-
lowering therapy; history of microvascular complications (including
nephropathy [presence of chronic kidney disease and/or albuminuria],
retinopathy [history of retinopathy or retinal laser photocoagulation],
and neuropathy [autonomic neuropathy, peripheral neuropathy and
erectile dysfunction]); and history of macrovascular complications
(including coronary artery disease [history of coronary artery disease,
angina, myocardial infarction, percutaneous coronary intervention,
and coronary artery bypass grafting], cerebrovascular disease [stroke,
transient ischaemic attack, carotid artery stenting and carotid endar-
terectomy], peripheral artery disease [history of peripheral artery dis-
ease including revascularization procedures, diabetic foot, and
amputation], heart failure, and implantable cardioverter defibrillator
use). Gross national income was also included in the models, using
2016 data from the World Bank (Classification of DISCOVER coun-
tries by gross national income in 2016 is shown in Figure S1).20 Com-
plete data were available for 81.7% of patients included in the model.
Separate models were also used to assess the association between
receiving education on diabetes management in the past year and
having poor glycaemic control. These models did not include data
from Japan because data for this variable were not collected in this
country. Multiple imputation was used in multivariable analyses to
account for unreported data and missing values. Imputation was car-
ried out using IVEware (University of Michigan). All other statistical
analyses were carried out using the SAS statistical software system
(SAS Institute, Inc., Cary, North Carolina).
3 | RESULTS
The demographics and characteristics of the DISCOVER cohort
(N = 15 992) at initiation of second-line therapy have been reported
previously.21 Characteristics of patients with available HbA1c data
(N = 11 891) are presented in Table 1. Overall, most patients were
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TABLE 1 Patient characteristics, overall and according to glycated haemoglobin category
Total HbA1c <7.0%
HbA1c 7.0%
to <8.0%
HbA1c 8.0%
to <9.0%
HbA1c ≥9.0%
(N = 11 891) (n = 2071) (n = 3840) (n = 2804) (n = 3176)
Men, n (%) 6657 (56.0) 1134 (54.8) 2129 (55.5) 1585 (56.5) 1809 (57.0)
Gender data missing 4 2 2 0 0
Self-reported ethnicity, n (%)
White 3403 (30.0) 581 (29.8) 1195 (32.6) 829 (30.8) 798 (26.2)
Black 128 (1.1) 22 (1.1) 42 (1.1) 22 (0.8) 42 (1.4)
Asian 4892 (43.1) 992 (50.8) 1653 (45.1) 1016 (37.7) 1231 (40.4)
Hispanic 661 (5.8) 110 (5.6) 192 (5.2) 154 (5.7) 205 (6.7)
Arabic 2019 (17.8) 209 (10.7) 509 (13.9) 610 (22.7) 691 (22.7)
Mixed 110 (1.0) 14 (0.7) 33 (0.9) 19 (0.7) 44 (1.4)
Other 142 (1.3) 23 (1.2) 40 (1.1) 42 (1.6) 37 (1.2)
Missing 536 120 176 112 128
Time in formal education, n (%)
No formal education 322 (3.0) 27 (1.5) 93 (2.7) 82 (3.2) 120 (4.2)
Primary (1–6 y) 1609 (14.9) 230 (12.6) 460 (13.2) 391 (15.1) 528 (18.3)
Secondary (7–13 y) 5348 (49.6) 950 (51.9) 1803 (51.9) 1247 (48.3) 1348 (46.7)
Higher (>13 y) 3497 (32.5) 625 (34.1) 1118 (32.2) 863 (33.4) 891 (30.9)
Missing 1115 239 366 221 289
Age, y 57.7 (12.1) 60.5 (12.3) 59.3 (12.0) 57.5 (12.0) 54.1 (11.3)
Missing 0 0 0 0 0
Time since diagnosis, years 5.7 (5.3) 5.4 (5.2) 6.0 (5.4) 5.8 (5.1) 5.5 (5.3)
Missing 325 81 116 61 67
HbA1c, % 8.3 (1.7) 6.4 (0.4) 7.5 (0.3) 8.4 (0.3) 10.5 (1.4)
FPG, mmol/L 9.5 (3.1) 7.1 (1.6) 8.3 (1.8) 9.6 (2.3) 12.2 (3.6)
Missing 3207 624 1108 722 753
BMI, kg/m2 29.4 (6.0) 29.0 (6.2) 29.1 (5.8) 29.8 (5.7) 29.7 (6.2)
Missing 790 114 226 184 266
Tobacco smoking, n (%)
Non-smoker 7771 (67.0) 1284 (63.8) 2456 (65.8) 1918 (69.9) 2113 (68.1)
Ex-smoker 2088 (18.0) 466 (23.1) 717 (19.2) 433 (15.8) 472 (15.2)
Current smoker 1737 (15.0) 263 (13.1) 562 (15.0) 392 (14.3) 520 (16.7)
Missing 295 58 105 61 71
SBP, mm Hg 132.6 (16.4) 131.6 (16.6) 132.6 (16.1) 133.0 (15.9) 132.9 (17.2)
Missing 513 73 158 109 173
History of microvascular diseasea, n (%) 2567 (21.6) 444 (21.4) 812 (21.2) 575 (20.5) 736 (23.2)
Missing 11 1 6 2 2
History of macrovascular diseaseb, n (%) 1732 (14.6) 354 (17.2) 623 (16.3) 385 (13.8) 370 (11.7)
Missing 35 8 14 5 8
Received education on diabetes
management in the past year, n (%)
6722 (75.0) 1057 (77.0) 2007 (72.7) 1694 (75.3) 1964 (75.9)
NAc 1865 531 789 304 241
Missing 1059 168 292 250 349
Comedications, n (%)
ASA 2042 (17.2) 331 (16.0) 662 (17.2) 526 (18.8) 523 (16.5)
Statins 5460 (45.9) 988 (47.7) 1834 (47.8) 1307 (46.6) 1331 (41.9)
(Continues)
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Asian (43.1%) or white (30.0%), and 56.0% of participants were men.
The mean (SD) age was 57.7 (12.1) years and the mean (SD) BMI and
time since diagnosis of T2D were 29.4 (6.0) kg/m2 and 5.7 (5.3) years,
respectively.
3.1 | Patterns of glycaemic control by country and
region
Overall, HbA1c data were available for 11 891 patients (80.9%; ARR
57.5%-98.2%), with substantial variation between countries (Tables 2
and 3). FPG data were available for 70.3% of patients (ARR 36.2%-
84.5%), and 13 546 patients (92.2%) had either HbA1c or FPG data
available (ARR 59.2%-99.1%; Table 2). Among countries, the propor-
tions of patients with either HbA1c or FPG measurements available
ranged from 36.8% to 100.0% (Table 3). Reasons for changing therapy
among patients with or without available HbA1c or FPG data, as well
as according to country income, are shown in Table S2. In both patient
populations, lack of efficacy was the most commonly stated reason
for changing therapy, although this was more common in patients
with HbA1c or FPG measurements than in patients without available
measurements (90.5% vs 67.7% of patients). Physician preference,
patient request and side effects were more commonly stated as
TABLE 1 (Continued)
Total HbA1c <7.0%
HbA1c 7.0%
to <8.0%
HbA1c 8.0%
to <9.0%
HbA1c ≥9.0%
(N = 11 891) (n = 2071) (n = 3840) (n = 2804) (n = 3176)
ACE inhibitors/ARBs 4727 (39.8) 844 (40.8) 1617 (42.1) 1149 (41.0) 1117 (35.2)
Diuretics 1421 (12.0) 275 (13.3) 476 (12.4) 350 (12.5) 320 (10.1)
β-blockers 1702 (14.3) 332 (16.0) 555 (14.5) 444 (15.8) 371 (11.7)
First-line therapy, n (%)
MET monotherapy 6961 (58.5) 1232 (59.5) 2398 (62.5) 1610 (57.4) 1721 (54.2)
SU monotherapy 805 (6.8) 139 (6.7) 231 (6.0) 217 (7.7) 218 (6.9)
DPP-4 inhibitor monotherapy 1122 (9.4) 304 (14.7) 453 (11.8) 206 (7.3) 159 (5.0)
Other monotherapy 445 (3.7) 146 (7.0) 167 (4.4) 73 (2.6) 59 (1.9)
MET + SUs 1525 (12.8) 137 (6.6) 323 (8.4) 399 (14.2) 666 (21.0)
MET + DPP-4 inhibitors 425 (3.6) 61 (2.9) 115 (3.0) 116 (4.1) 133 (4.2)
MET + otherd 131 (1.1) 14 (0.7) 49 (1.3) 41 (1.5) 27 (0.9)
Other combinations 476 (4.0) 38 (1.8) 103 (2.7) 142 (5.1) 193 (6.1)
Missing 1 0 1 0 0
Second-line therapy, n (%)
MET monotherapy 194 (1.6) 99 (4.8) 52 (1.4) 21 (0.7) 22 (0.7)
SU monotherapy 322 (2.7) 93 (4.5) 96 (2.5) 57 (2.0) 76 (2.4)
DPP-4 inhibitor monotherapy 531 (4.5) 210 (10.1) 194 (5.1) 78 (2.8) 49 (1.5)
Other monotherapy 348 (2.9) 96 (4.6) 106 (2.8) 81 (2.9) 65 (2.0)
MET + SU 2227 (18.7) 280 (13.5) 684 (17.8) 585 (20.9) 678 (21.3)
MET + DPP-4 inhibitors 3250 (27.3) 607 (29.3) 1294 (33.7) 760 (27.1) 589 (18.5)
MET + otherc 1164 (9.8) 260 (12.6) 431 (11.2) 236 (8.4) 237 (7.5)
Other combinations 3131 (26.3) 394 (19.0) 904 (23.5) 843 (30.1) 990 (31.2)
Insulin 723 (6.1) 32 (1.5) 78 (2.0) 143 (5.1) 470 (14.8)
Missing 1 0 1 0 0
Data are reported as mean (SD), unless otherwise stated. Percentages are calculated for all patients with data available; missing data are excluded.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; ASA, acetylsalicylic acid; BMI, body mass index; DPP-4, dipeptidyl
peptidase-4; FPG, fasting plasma glucose; HbA1c, glycated haemoglobin; MET, metformin; NA, not available; SBP, systolic blood pressure; SU,
sulphonylurea.
aIncludes nephropathy (presence of chronic kidney disease and/or albuminuria), retinopathy (history of retinopathy or retinal laser photocoagulation), and
neuropathy (autonomic neuropathy, peripheral neuropathy, and erectile dysfunction).
bIncludes coronary artery disease (history of coronary artery disease, angina, myocardial infarction, percutaneous coronary intervention, and coronary
artery bypass grafting), cerebrovascular disease (stroke, transient ischaemic attack, carotid artery stenting, and carotid endarterectomy), peripheral artery
disease (history of peripheral artery disease including revascularization procedures, diabetic foot, and amputation), heart failure, and implantable
cardioverter defibrillator use.
cThese patients are from Japan, where data on diabetes education were not collected.
dExcluding insulin.
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reasons for changing therapy in patients without available HbA1c or
FPG measurements than in patients with available measurements
(16.5% vs 5.1%, 4.2% vs 1.3% and 6.2% vs 4.7%, respectively). Effi-
cacy was the most commonly stated reason for choosing a second-
line therapy in both patient populations.
The overall mean (SD; ARR) HbA1c level at initiation of second-
line therapy was 8.3 (1.7; 7.9-8.7)% (Table 2). Mean HbA1c levels
were highest in the Eastern Mediterranean region and lowest in the
Western Pacific region (8.7% and 7.9%, respectively). The overall pro-
portions of patients with HbA1c <8.0%, ≥8.0 to <9.0% and ≥9.0%
were 49.8%, 23.6% and 26.7%, respectively. These proportions varied
across countries and regions (Figure 1).
As expected in a population of patients initiating second-line
glucose-lowering therapy, the overall proportion of patients with
HbA1c <7.0% among patients with available values was low (17.4%,
ARR 9.6%-25.8%; Figure 1). The mean (SD) HbA1c among these
patients was 6.4 (0.4)% (Table 1), and the reasons for changing ther-
apy are presented in Table S3. As in the overall cohort, the majority of
patients (72.3%) with HbA1c <7.0% changed first-line therapy owing
to lack of efficacy (ARR 56.9%-85.8%). The most common reasons for
choosing a second-line therapy were expected efficacy (39.7%, ARR
15.4%-70.8%) and tolerability (22.7%, ARR 5.3%-36.2%). The propor-
tion of patients with HbA1c <7.0% was particularly low in Africa
(12.2%), South-East Asia (13.4%), and the Eastern Mediterranean
region (9.6%), and was highest in Europe and the Western Pacific
region (18.7% and 25.8%, respectively). The proportion of patients
with HbA1c ≥9.0% varied substantially across regions, with the
highest proportions in South-East Asia (35.6%) and the Eastern Medi-
terranean region (33.9%). In total, 19 countries had >25% of patients
with HbA1c ≥9.0% at initiation of second-line therapy.
3.2 | Factors associated with poor glycaemic control
at initiation of second-line therapy
Figure 2 shows the factors associated with poor glycaemic control,
defined as HbA1c >8.0%, at initiation of second-line therapy. In this
model, young patients were more likely to have poor glycaemic
control at the time of treatment intensification than old patients, and
the odds of having poor glycaemic control decreased with each
10-year age increment. The following factors were also associated
with poor glycaemic control: male sex; having a low level of education
versus >13 years of formal education; being a current smoker; having
high SBP (per 10 mm Hg increment); having a time since T2D diagno-
sis of >10 years; not taking statins; receiving sulphonylurea
(SU) monotherapy, an SU or dipeptidylpeptidase-4 (DPP-4) inhibitor in
combination with metformin or another combination of two or more
agents as first-line treatment, versus metformin; and having a history
of microvascular complications. Additionally, patients in lower-middle-
income countries were more likely to have HbA1c levels >8.0% than
patients from high-income countries. Results of analyses using thresh-
olds of 7.0% or 9.0% to define poor glycaemic control (Figure S2) were
similar to those of the primary analysis. There was no significant associ-
ation between receiving education on diabetes management in the past
year and the likelihood of having HbA1c levels >8.0%, when assessed
in patients for whom this information was collected (Figure S3).
4 | DISCUSSION
The present analysis of data from the DISCOVER study programme
revealed consistently high HbA1c levels at initiation of second-line
therapy across countries and regions worldwide. Approximately 50%
of patients with available HbA1c measurements had HbA1c >8.0%,
and >25% had HbA1c >9.0%. Overall, <20% of patients had HbA1c
<7.0%. Many patients did not have available HbA1c measurements,
despite a decision to initiate second-line therapy having been made,
which highlights an opportunity for improvement of the quality of
care of patients with T2D.
Although previous studies have reported poor levels of glycaemic
control among patients with T2D,22-24 these have mostly been con-
ducted in populations of patients with more advanced disease than in
the present study. For example, the A1chieve study
25 was a global,
prospective, observational study of patients with T2D who were initi-
ating insulin therapies in routine clinical practice. That study included
TABLE 2 Glycated haemoglobin and fasting plasma glucose data and availability, by region
Overall Africa Americas South-East Asia Europe
Eastern
Mediterranean
Western Pacific
(N = 14 699) (n = 812) (n = 2002) (n = 3360) (n = 3479) (n = 2182) (n = 2864)
Mean (SD) HbA1c, %, 8.3 (1.7) 8.6 (1.9) 8.5 (1.9) 8.6 (1.7) 8.1 (1.6) 8.7 (1.6) 7.9 (1.6)
Mean (SD) FPG, mmol/L 9.5 (3.1) 9.7 (3.5) 9.8 (3.4) 9.3 (3.0) 9.3 (3.0) 10.2 (3.3) 8.9 (2.8)
Availability of data, n (%)
With HbA1c data 11 891 (80.9) 467 (57.5) 1531 (76.5) 2052 (61.1) 3003 (86.3) 2046 (93.8) 2792 (97.5)
HbA1c and FPG data 8684 (59.1) 280 (34.5) 1180 (58.9) 1706 (50.8) 2306 (66.3) 1774 (81.3) 1438 (50.2)
HbA1c data only 3207 (21.8) 187 (23.0) 351 (17.5) 346 (10.3) 697 (20.0) 272 (12.5) 1354 (47.3)
With FPG data only 1655 (11.3) 14 (1.7) 211 (10.5) 1030 (30.7) 285 (8.2) 70 (3.2) 45 (1.6)
No HbA1c or FPG data 1153 (7.8) 331 (40.8) 260 (13.0) 278 (8.3) 191 (5.5) 66 (3.0) 27 (0.9)
Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.
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patients from 30 countries across four continents (Asia, Africa, South
America and Europe); 21 of these countries were included in DIS-
COVER. In A1chieve, the mean baseline HbA1c was higher than that
in DISCOVER participants (9.5% vs 8.3%), which is likely to reflect the
more severe diabetic phenotype in patients who are initiating insulin
therapies. Similarly, the IMPROVE study, which included >50 000
patients across eight countries with a mean diabetes duration of
6.9 years, reported a mean HbA1c of 9.4%.26 In the multinational,
prospective International Diabetes Management Practice Study
(IDMPS) survey, the mean HbA1c and mean diabetes duration were
TABLE 3 Availability of glycated haemoglobin and fasting plasma glucose data, by country
Region Country
With HbA1c and
FPG data
With HbA1c data only With FPG data only No HbA1c or FPG data
Overall – n = 8684 (59.1) n = 3207 (21.8) n = 1655 (11.3) n = 1153 (7.8)
Africa Algeria 207 (70.6) 75 (25.6) 8 (2.7) 3 (1.0)
South Africa 73 (14.1) 112 (21.6) 6 (1.2) 328 (63.2)
Americas Argentina 222 (74.2) 35 (11.7) 23 (7.7) 19 (6.4)
Brazil 309 (70.7) 95 (21.7) 14 (3.2) 19 (4.3)
Canada 230 (59.6) 50 (13.0) 4 (1.0) 102 (26.4)
Colombia 140 (68.0) 38 (18.4) 10 (4.9) 18 (8.7)
Costa Rica 52 (40.9) 50 (39.4) 8 (6.3) 17 (13.4)
Mexico 179 (39.3) 70 (15.4) 143 (31.4) 63 (13.8)
Panama 48 (52.2) 13 (14.1) 9 (9.8) 22 (23.9)
South-East Asia India 1599 (50.9) 327 (10.4) 962 (30.6) 251 (8.0)
Indonesia 107 (48.4) 19 (8.6) 68 (30.8) 27 (12.2)
Europe Austria 156 (74.6) 39 (18.7) 1 (0.5) 13 (6.2)
Czech Republic 357 (78.6) 83 (18.3) 4 (0.9) 10 (2.2)
Denmark 2 (4.9) 30 (73.2) 0 (0.0) 9 (22.0)
France 204 (77.3) 40 (15.2) 4 (1.5) 16 (6.1)
Italy 327 (90.6) 29 (8.0) 4 (1.1) 1 (0.3)
Netherlands 143 (88.3) 13 (8.0) 3 (1.9) 3 (1.9)
Norway 3 (3.8) 65 (82.3) 1 (1.3) 10 (12.7)
Poland 160 (49.4) 84 (25.9) 39 (12.0) 41 (12.7)
Russia 276 (46.9) 70 (11.9) 199 (33.8) 43 (7.3)
Spain 195 (86.7) 16 (7.1) 10 (4.4) 4 (1.8)
Sweden 16 (6.8) 198 (83.9) 0 (0.0) 22 (9.3)
Turkey 467 (87.1) 30 (5.6) 20 (3.7) 19 (3.5)
Eastern Mediterranean Bahrain 55 (78.6) 15 (21.4) 0 (0.0) 0 (0.0)
Egypt 489 (83.9) 45 (7.7) 45 (7.7) 4 (0.7)
Jordan 208 (76.8) 40 (14.8) 7 (2.6) 16 (5.9)
Kuwait 48 (94.1) 3 (5.9) 0 (0.0) 0 (0.0)
Lebanon 277 (79.6) 54 (15.5) 2 (0.6) 15 (4.3)
Oman 21 (67.7) 10 (32.3) 0 (0.0) 0 (0.0)
Saudi Arabia 402 (77.5) 80 (15.4) 7 (1.3) 30 (5.8)
Tunisia 191 (89.3) 14 (6.5) 9 (4.2) 0 (0.0)
United Arab Emirates 83 (87.4) 11 (11.6) 0 (0.0) 1 (1.1)
Western Pacific Australia 92 (55.1) 66 (39.5) 1 (0.6) 8 (4.8)
Japan 691 (37.0) 1174 (62.8) 0 (0.0) 4 (0.2)
Malaysia 257 (76.9) 32 (9.6) 37 (11.1) 8 (2.4)
Korea, South 163 (69.1) 68 (28.8) 2 (0.8) 3 (1.3)
Taiwan 235 (91.1) 14 (5.4) 5 (1.9) 4 (1.6)
Data are reported as n (%).
Abbreviations: FPG, fasting plasma glucose; HbA1c, glycated haemoglobin.
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7.8% and 8.4 years, respectively, among patients with T2D.11 The
IDMPS study cohort comprised 9901 patients with T2D from Asia
(Korea, China, Indonesia, India, Hong Kong, Taiwan, Malaysia and
Thailand), Eastern Europe (Romania, Bulgaria, Turkey, Tunisia and
Bosnia), Latin America (Argentina, Ecuador, Venezuela and Columbia),
and Africa (Tunisia), many of whom were receiving insulin therapy. In
the context of these studies of patients with presumably more severe
diabetes than patients in the present study, the poor overall glycaemic
control among DISCOVER patients is concerning.
The mean HbA1c at initiation of second-line therapy and the pro-
portion of patients with HbA1c ≥9.0% were generally higher in lower-
middle- and upper-middle-income countries than in high-income
countries. Particularly concerning regions were parts of Asia and
Africa, as well as the Middle-Eastern region. Consistent with this find-
ing, results from the multivariate analysis showed that living in a
lower-middle-income country was strongly associated with poor
glycaemic control (HbA1c >8.0%) relative to living in a high-income
country; this result was also seen when a threshold of 9.0% was used
Overall cohort (n = 11 891)
Overall (n = 467)
Algeria  (n = 282)
South Africa  (n = 185)
Overall (n = 1531)
Argentina  (n = 257)
Brazil  (n = 404)
Canada  (n = 280)
Columbia  (n = 178)
Costa Rica  (n = 102)
Mexico  (n = 249)
Panama  (n = 61)
Overall (n = 2052)
India  (n = 1925)
Indonesia  (n = 126)
Overall (n = 3003)
Austria  (n = 195)
Czech Rep.  (n = 440)
Denmark  (n = 32)
France  (n = 244)
Italy  (n = 356)
Netherlands  (n = 156)
Norway  (n = 68)
Poland  (n = 244)
Russia  (n = 346)
Spain  (n = 211)
Sweden (n = 214)
Turkey  (n = 497)
Overall (n = 2046)
Bahrain  (n = 70)
Egypt  (n = 534)
Jordan  (n = 248)
Kuwait  (n = 51)
Lebanon  (n = 331)
Oman  (n = 31)
Saudi Arabia  (n = 482)
Tunisia  (n = 205)
UAE  (n = 94)
Overall (n = 2792)
Australia  (n = 158)
Japan  (n = 1865)
Malaysia  (n = 289)
South Korea  (n = 231)
Taiwan  (n = 249)
<7.0%
0 20 40
Proportion of patients (%)
60 80 100
7.0–7.9%
8.0–8.9%
≥9.0%
Africa
Americas
South-East Asia
Europe
Eastern
Mediterranean
Western
F IGURE 1 Proportions of patients in different glycated haemoglobin ranges at initiation of second-line therapy. UAE, United Arab Emirates
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in the analysis. This was not unexpected, given that low income is
likely to translate into reduced expenditure on healthcare. Indeed,
many of the countries included in DISCOVER have very low diabetes-
related healthcare expenditure compared with high-income coun-
tries.27 Likely consequences of this low expenditure on care for
patients with T2D include a lack of resources for HbA1c monitoring,
which may lead to delays in intensifying second-line glucose-lowering
therapies. Consistent with this hypothesis, over one-third of patients
in the South-East Asia and African regions lacked HbA1c measure-
ments in the present study. These findings are consistent with those
from the IDMPS survey, which revealed that 36% of patients with T2D
in developing regions had never had their HbA1c levels measured.11
Similarly, the authors of a study conducted in Brazil commented that
kits for HbA1c measurement are not routinely provided by the National
Brazilian Health Care System.28 Aside from HbA1c monitoring, patients
in lower-middle and upper-middle-income countries may also encoun-
ter problems with the availability and affordability of glucose-lowering
therapies compared with patients in high-income countries.29 Indeed,
in the present study, physicians cited cost and access to treatment as
reasons for choosing second-line therapy for 7.2% and 5.1% of
patients, respectively, and these proportions were higher in middle-
income countries than in high-income countries.
Mean levels of HbA1c were also well above guideline-
recommended values in many high-income countries. As with lower-
Age (per 10-year increment)
Male sex (vs. female)
Education (vs. higher education )
 No formal education
 Primary (1–6 years)
 Secondary (7–13)
Smoking status (vs. non-smoker)
 Ex-smoker
 Current smoker
BMI (per 5 kg/m2 increment)
SBP (per 10 mmHg increment)
Time since T2D diagnosis (vs. 0–5 years)
 5–10 years
 ≥10 years
Use of comedications
 ACE inhibitor/ARB
 ASA
 Diuretic
 β-blocker
 Statin
First-line therapy
 SU (mono) vs. MET (mono)
 DPP-4i (mono) vs. MET (mono)
 Other (mono) vs. MET (mono)
 MET + SU vs. MET (mono)
 MET + DPP-4i vs. MET (mono)
 MET + other vs. MET (mono)
 Other combinations vs. MET (mono)
Complications history
 Microvascular ‡
 Macrovascular §
Country income (vs. high)¶
 Lower-middle
 Upper-middle
0.79 (0.75, 0.82)
1.11 (1.02, 1.21)
1.69 (1.31, 2.17)
1.45 (1.26, 1.68)
1.22 (1.10, 1.34)
1.01 (0.90, 1.13)
1.25 (1.11, 1.41)
1.00 (0.96, 1.04)
1.07 (1.05, 1.10)
1.10 (1.00, 1.21)
1.16 (1.04, 1.31)
0.91 (0.84, 1.00)
1.01 (0.90, 1.13)
0.97 (0.85, 1.10)
0.99 (0.87, 1.12)
0.91 (0.84, 0.99)
1.22 (1.04, 1.43)
1.18 (0.97, 1.45)
0.93 (0.72, 1.19)
2.05 (1.80, 2.32)
1.52 (1.23, 1.87)
1.01 (0.70, 1.45)
2.19 (1.78, 2.71)
1.13 (1.03, 1.25)
0.92 (0.81, 1.05)
1.84 (1.18, 2.86)
1.39 (1.00, 1.93)
OR (95% CI)†
0.50.25 1
HbA 1c >8.0%
more likely
HbA 1c >8.0%
less likely
2 4
F IGURE 2 Multivariate analysis of
factors associated with poor glycaemic
control defined as glycated haemoglobin
(HbA1c) >8.0%. †The plot shows odds
ratios, adjusted for all variables in the
figure, using a hierarchical logistic model
as described in the methods. HbA1c is
modelled as a dichotomous variable.
‡Includes nephropathy (presence of
chronic kidney disease and/or
albuminuria), retinopathy (history of
retinopathy or retinal laser
photocoagulation), and neuropathy
(autonomic neuropathy, peripheral
neuropathy, and erectile dysfunction).
§Includes coronary artery disease (history
of coronary artery disease, angina,
myocardial infarction, percutaneous
coronary intervention, and coronary
artery bypass grafting), cerebrovascular
disease (stroke, transient ischaemic attack,
carotid artery stenting, and carotid
endarterectomy), peripheral artery disease
(history of peripheral artery disease
including revascularization procedures,
diabetic foot, and amputation), heart
failure, and implantable cardioverter
defibrillator use. ¶Categorized using the
2016 World Bank classification. ACE,
angiotensin-converting enzyme; ARB,
angiotensin receptor blocker; ASA,
acetylsalicylic acid; BMI, body mass index;
CI, confidence interval; DPP-4, dipeptidyl
peptidase-4; MET, metformin; mono,
monotherapy; OR, odds ratio; SBP,
systolic blood pressure; SU,
sulphonylureas; T2D, type 2 diabetes
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middle and upper-middle-income countries, this finding may reflect
delays in treatment intensification but for different reasons. A possi-
ble contributing factor is conservative management of patients by cli-
nicians, as has been documented previously.16,30 In addition, the
current stepwise approach to treatment intensification that is advo-
cated by major treatment guidelines may lead to prolonged periods of
hyperglycaemia in between steps.15,31 A recent analysis of patients in
the United States showed no improvements in overall glycaemic con-
trol and an increase in the proportion of patients with HbA1c ≥9.0%
between 2006 and 2013, despite increased utilization of newer and
costlier glucose-lowering agents among these patients.32 These data,
combined with the present data, highlight a pressing need to re-
evaluate existing treatment pathways for patients with T2D in order
to improve glycaemic control.
Other factors associated with poor glycaemic control in multivari-
ate analyses included younger age, male sex, low education level, and
use of combination glucose-lowering therapies as first-line diabetes
treatment. The inverse relationship between age and glycaemic con-
trol, while somewhat counter-intuitive, might be explained by older
patients being monitored more closely by physicians than younger
patients, owing to their increased comorbidity and heightened risk of
complications. Authors of other studies have also hypothesized that
older patients might be more motivated to look after their health and
adhere to their medications than young patients.33 Patients with a
high level of education are likely to have better means to fund treat-
ment or private medical care than less educated patients, and there is
some evidence of a correlation between education level and the qual-
ity of diabetes care and outcomes.34 This hypothesis is also consistent
with the association seen in our data between lower country income
and poor glycaemic control. As might be expected, having a time since
diagnosis of T2D of at least 10 years compared with 0 to 5 years was
also strongly correlated with poor glycaemic control. This finding is
consistent with other observational studies that have demonstrated a
positive relationship between disease duration and poor glycaemic
control.35,36 The trend is likely to reflect the continual decline in β-cell
function that is characteristic of T2D. These findings emphasize the
importance of intensifying treatment in a timely manner once HbA1c
is no longer controlled by first-line therapy.
The positive association between use of combination glucose-
lowering therapy as first-line treatment and poor glycaemic control is
probably explained by the fact that patients with high HbA1c levels at
the time of diagnosis require more intensive pharmacological treat-
ment than patients with lower HbA1c levels, as per clinical guideline
recommendations.6 However, these intensive treatments may fail to
control glycaemia adequately, which is why HbA1c levels could
remain high and require initiation of second-line therapy. As described
previously,21,37 our findings also showed a positive association
between having a history of microvascular complications and having
HbA1c levels >8.0%. This finding is consistent with evidence that
intensive glycaemic control for a prolonged period decreases the inci-
dence of microvascular complications.37 However, longitudinal data
from DISCOVER are required to confirm a relationship between
changes in HbA1c trajectories and the incidence of diabetes complica-
tions in the present study cohort.
An interesting finding in the present study was that close to 20%
of patients in the study cohort had HbA1c <7.0%. This was somewhat
unexpected, given that this is a population of patients who are initiat-
ing second-line glucose-lowering therapy. The finding that the major-
ity of these patients cited efficacy as the reason for changing
treatment was also surprising, although it is notable that this propor-
tion of patients was lower than in the overall population of patients
with available HbA1c or FPG measurements. Similarly, although
almost half of patients with HbA1c <7.0% cited efficacy as a reason
for choosing a second-line therapy, this was lower than in the overall
patient population. It could be the case that the patients with HbA1c
<7.0% in the present study were early in their disease trajectory and
therefore had been set HbA1c targets below 7.0% by their physicians,
consistent with guideline recommendations for patients with few
comorbidities and low risk of hypoglycaemia.7
Within the study cohort, there were large numbers of patients
without available data on the extent of glycaemic control. As
highlighted previously, this was particularly evident in lower-middle
and upper-middle-income countries in which physicians may not mon-
itor HbA1c levels routinely, owing to the high cost of this practice
compared with obtaining other measures of glycaemic control. Many
patients who lacked HbA1c data in the present cohort had FPG data
instead, which suggests that FPG may be used as an alternative to
HbA1c to monitor glycaemia and to support treatment change deci-
sions in some countries. While there is some evidence to suggest a
good correlation between HbA1c and FPG measurements within a
certain range,38 this practice is contradictory to treatment guidelines.
Overall, 7.8% of the cohort had neither HbA1c nor FPG data available,
and this proportion was particularly high (40.8%) in the African region.
It is concerning that in some countries, 10% to 20% of patients
switched glucose-lowering therapy in the absence of FPG or HbA1c
measurements to direct this decision. Although one might expect that
this would be due to concerns about cost or tolerability, it is notable
that the proportions of patients for whom these factors were
recorded as reasons for changing therapy were low, despite being
slightly higher in patients without FPG or HbA1c measurements than
in patients for whom these measurements were available.
Key strengths of the DISCOVER study programme include the
large numbers of patients and inclusion of many lower-middle and
upper-middle-income countries which have rarely or never been stud-
ied before.17 The use of a standardized electronic case report form for
data collection allows comparison of results within and across coun-
tries and regions. As DISCOVER is a longitudinal study, data collected
during follow-up will provide valuable insights into the relationship
between glycaemic control and clinical outcomes in patients with T2D
across the globe. The results reported in this manuscript provide con-
text for the interpretation of these follow-up data. There are also
potential limitations of DISCOVER. Although study sites were
selected with the intention of providing a patient population that was
as representative of T2D care in each country as possible,19 attain-
ment of a truly representative sample is inherently difficult to achieve
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in large international studies. Reasons for this include infrastructure
challenges, and the fact that some primary care centres are not set up
for or willing to participate in observational research. Such practical
constraints resulted in urban locations and secondary care centres
being over-represented in this study. Moreover, levels of education
seen in our patient population are higher on average than would be
expected. This potential selection bias is likely to lead to an over-
estimation of the quality of diabetes care, since better-educated
patients in urban locations would be expected to receive better
healthcare than less educated patients in rural locations.19 Thus, the
level of glycaemic control at initiation of second-line treatment across
the DISCOVER countries may be even worse than the findings
reported in the present study. Despite these limitations, the efforts
made to maximize representativeness resulted in the inclusion of a
heterogeneous patient population, as well as a diverse range of sites
and physicians. Overall, ethnicity and sex distributions of DISCOVER
patients were in agreement with corresponding data from the 2017
Atlas of the International Diabetes Federation.19 The high proportion
of missing data in several countries, which might have reduced the
precision of the multivariate analysis where imputation was used to
compensate for unreported data, should also be acknowledged. How-
ever, this is likely to be reflective of routine clinical care; for example,
HbA1c is not routinely measured in some clinical settings.
In conclusion, data from the DISCOVER study confirmed that
therapeutic inertia is a global phenomenon with consistently high
HbA1c levels at initiation of second-line glucose-lowering therapy,
particularly in lower-middle and upper-middle-income countries.
Globally, there are large numbers of patients with very poor glycaemic
control (HbA1c ≥9.0%) at initiation of second-line glucose-lowering
therapy, suggesting that treatment is not intensified in a timely man-
ner as recommended by clinical guidelines. Factors associated with
poor glycaemic control included low education level, low country
income, and longer time since diagnosis of diabetes. Despite guideline
recommendations, HbA1c was not routinely measured in all countries,
perhaps owing to the higher cost of HbA1c measurements in lower-
middle-income countries than in high-income countries. These find-
ings suggest a need for better monitoring of glycaemic control in
patients with T2D worldwide, as well as interventions to improve
HbA1c control at early stages of the disease.
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